Access to Asthma Medicines in Exchanges

Asthma is a common, chronic lung disease that inflames and narrows the airways. Asthma causes recurring periods of wheezing, chest tightness, shortness of breath, and coughing. Asthma affects people of all ages, but it most often starts during childhood. In the United States, more than 25 million people are known to have asthma, including about 7 million children. Goals of asthma treatment are reduced impairment from symptoms; minimized risk of asthma attacks and other adverse outcomes, such as hospitalizations and loss of lung function; and minimized side effects of asthma medicines.

Restricting Access to Medicines At the Expense of Patients Warrants a Candid Conversation

06.23.14 | By

It has become increasingly clear in recent weeks that far too many patients simply cannot access innovative medicines that help treat costly chronic diseases. While more Americans now have health care coverage under the Affordable Care Act (ACA), they still face insurmountable barriers to access that hinder our collective efforts to prevent, manage, and cure these conditions.

Investments in Innovation, Jobs, and Economic Development

06.20.14 | By

Innovation is the engine of economic growth and development.  Research and development (R&D) spending is what creates jobs and makes innovation a reality.  As the global economy continues to recover and regain its former strength, the pharmaceutical industry remains the world’s largest source of R&D spending.  According to a recent article in the

Week in Review: The Importance of Patient Perspectives

06.20.14 | By

“The biopharmaceutical industry’s top priority is to provide patients with access to innovative, life-saving medicines.”

Over 3 Million Dollars Available for Young Scientists

06.19.14 | By

For nearly 50 years the PhRMA Foundation has helped thousands of scientists advance their careers and has inspired new generations to enter biopharmaceutical research. The early-career support provided by the PhRMA Foundation has been a catalyst for scientists to become leaders in their organizations and fields. Their programs help build a larger pool of highly-trained researchers to meet the growing needs of academic institutions, the government and the research-intensive pharmaceutical industry. Are you one of them?

Understanding Health Insurance Exchanges State-by-State

06.19.14 | By

It’s no secret that when it comes to the Affordable Care Act, health insurance exchange coverage varies depending on where you live. From the plans offered, to premiums, to the type of Marketplace, not every state looks alike.

That’s why we created state-by-state fact sheets on health insurance exchange coverage and access to prescription medicines across the country.

First Technology Pilot Program Shares Perspective of Sickle Cell Disease Community with FDA

06.18.14 | By

In the guest blog below, Michele Lloyd-Puryear, Special Consultant to Genetic Alliance, discusses key findings from a patient-driven data collection effort intended to complement the Food and Drug Administration’s (FDA) patient-focused drug development initiative which was part of the most recent reauthorization of the Prescription Drug User Fee Act.

More than 430 Medicines in Development to Treat Chronic Diseases Affecting Older Americans

06.18.14 | By

Aging is a fact of life but the good news is that life expectancy continues to climb and more and more Americans are living fuller, richer lives thanks in large part to innovative medicines being developed by biopharmaceutical companies. As the baby boomer generation reaches retirement age, the demands on our health care system will continue to rise due to the increasing prevalence of chronic diseases affecting seniors.

Charles River Associates Releases Updated HTA Comparison Report

Washington, D.C., Brussels (June 17, 2014) — Charles River Associates today announced the release of a report at the HTAi Annual Meeting titled “A Comparative Analysis of the Role and Impact of Health Technology Assessment.”  The report, commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA), updates a previous study conducted in 2011. 

Patient Reported Outcomes as a Means to Reaching Effective Quality Measurement

06.17.14 | By

A recent Roundtable in Washington D.C. underscored why, with the growing focus on value-based payment in health care, it’s more important than ever to focus on the patient. We can’t advance patient-centered care if we aren’t measuring and incentivizing what matters to patients. We have begun to see this shift in the premarket arena via patient-focused drug development and in comparative effectiveness research at the Patient-Centered Outcomes Research Institute.

Pages

Subscribe to RSS - Opinion